Loading clinical trials...
Loading clinical trials...
A 2-part Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) Administered to Adults With Major Depressive Disorder at Imminent Risk of Suicide
Conditions
Interventions
SLS-002
Placebo
+2 more
Locations
21
United States
Seelos Investigational Site
Orange, California, United States
Seelos Investigational Site
Panorama City, California, United States
Seelos Investigational Site
San Diego, California, United States
Seelos Investigational Site
Hollywood, Florida, United States
Seelos Investigational Site
Miami, Florida, United States
Seelos Investigational Site
Miami Lakes, Florida, United States
Start Date
December 17, 2020
Primary Completion Date
June 17, 2023
Completion Date
July 14, 2023
Last Updated
September 28, 2023
NCT07025720
NCT07432438
NCT07238192
NCT05256940
NCT06315075
NCT06778278
Lead Sponsor
Seelos Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions